Role of erythropoietin in the treatment of lung cancer associated anaemia

Lung Cancer

Volumn 34, Issue SUPPL. 4, 2001, Pages 91-94

  Scagliotti, G V ^a   Novello, S ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Anaemia; Erythropoietin; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYANOCOBALAMIN; CYTOKINE; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; BLOOD TRANSFUSION; CONFERENCE PAPER; ERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; HYPOXIA; LUNG CANCER; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0035202631     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00398-1     Document Type: Conference Paper

References (15)

1. Erythropoiesis, erythropoietin and iron
2. Cisplatin-associated anaemia: a erythropoietin deficiency syndrome
3. Transfusion support for leukemia and oncology patients
4. Large scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
5. The frequency of red cell transfusion for anaemia in patients receiving chemotherapy. A retrospective cohort study
6. Radiotherapy and anaemia: the clinical experience
7. The impact of radiation-related factors upon long term outcome in the management of advanced head and neck carcinoma treated with supradose intra-arterial targeted cisplatino and radiation therapy
8. Preliminary report of a double blind, placebo controlled studies using human recombinant erythropoietin (rHuEPO) in the anaemia associated with cancer
9. Use of recombinant human erythropoietin in the treatment of anaemia in patients who have cancer
10. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anaemia: results of a double-blind and open-label follow-up studies
11. Impact of therapy with epoietin alfa on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice
12. Quality of life benefit in chemotherapy patients treated with epoietin alfa is independent of disease response or tumour type. Results from a prospective community oncology study
13. Once-weekly dosing of epoietin alfa is similar to three times weekly dosing in increasing haemoglobin and quality of life